2026-04-17T03:48:33Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/109132025-10-24T10:42:44Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Chiu, Shao-Ming author Park, Jun Yong author Seto, Wai-Kay author Sonneveld, Milan author Brakenhoff, Sylvia author Kaewdech, Apichat author Buti Ferret, Maria author 2024-01-26T11:08:44Z 2024-01-26T11:08:44Z 2024-01 Clinical Relapse; HBsAg Loss Recaiguda clínica; Pèrdua d'HBsAg Recaída Clínica; Pérdida de HBsAg Background & Aims Patients who discontinue nucleo(s)tide analogue therapy are at risk of viral rebound and severe hepatitis flares, necessitating intensive off-treatment follow-up. Methods We studied the association between hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA levels at off-treatment follow-up week 24 (FU W24), with subsequent clinical relapse, and HBsAg loss in a multicenter cohort of hepatitis B e antigen (HBeAg)–negative patients with chronic hepatitis B who discontinued nucleo(s)tide analogue therapy. Results We studied 475 patients, 82% Asian, and 55% treated with entecavir. Patients with higher HBV DNA levels at FU W24 had a higher risk of clinical relapse (hazard ratio [HR], 1.576; P < .001) and a lower chance of HBsAg loss (HR, 0.454; P < .001). Similarly, patients with higher HBsAg levels at FU W24 had a higher risk of clinical relapse (HR, 1.579; P < .001) and a lower chance of HBsAg loss (HR, 0.263; P < .001). A combination of both HBsAg <100 IU/mL and HBV DNA <100 IU/mL at FU W24 identified patients with excellent outcomes (9.9% clinical relapse and 58% HBsAg loss at 216 weeks of follow-up). Conversely, relapse rates were high and HBsAg loss rates negligible among patients with both HBsAg >100 IU/mL and HBV DNA >100 IU/mL (P < .001). Conclusions Among HBeAg-negative patients with chronic hepatitis B who discontinued antiviral therapy and who did not experience clinical relapse before FU W24, serum levels of HBV DNA and HBsAg at FU W24 can be used to predict subsequent clinical relapse and HBsAg clearance. A combination of HBsAg <100 IU/mL with HBV DNA <100 IU/mL identifies patients with a low risk of relapse and excellent chances of HBsAg loss and could potentially be used as an early surrogate end point for studies aiming at finite therapy in HBV. http://hdl.handle.net/11351/10913 Hepatitis B - Tractament Medicaments antivírics - Ús terapèutic Antígens CHEMICALS AND DRUGS::Biological Factors::Antigens::Antigens, Viral::Hepatitis Antigens::Hepatitis B Antigens::Hepatitis B Surface Antigens DISEASES::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis, Chronic::Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis B, Chronic CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::antígenos::antígenos víricos::antígenos de las hepatitis::antígenos de la hepatitis B::antígenos de superficie de la hepatitis B ENFERMEDADES::enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis crónica::enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis B crónica COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy